AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33605620
Drug: Nebulized amikacin
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nebulized amikacin at a dose of 40 mg/kg/day for 3-5 days
Trial: 33605620
Drug: Nebulized colistimethate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized colistimethate sodium (CMS) at a dose of 15 million IU/day for 3-5 days
Trial: 33605620
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of a new cephalosporine/ß-lactamase inhibitor for 7 days
Trial: 33605620
Drug: Nebulized CMS
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized CMS at a dose of 15 million IU/day for VAP caused by pandrug-resistant GNB
Trial: 33605620
Drug: Intravenous CMS
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous CMS at a dose of 9 million IU/day
Trial: 32741773
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day ubiquinol from 7 days before to 5 days after surgery
Trial: 36086930
Drug: Dexamethasone OMP
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone OMP (5 mg/week)
Trial: 34888277
Drug: Community-wide mass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-wide mass drug administration (cMDA) for soil-transmitted helminths (STH) delivered by CDDs.
Trial: 34520520
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (5 mcg/kg)
Trial: 34666202
Drug: Yogurt (220
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yogurt (220 g/d)
Trial: 34666202
Drug: Milk (220
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk (220 g/d)
Trial: 32129141
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of GO-ON (5 mL)
Trial: 32129141
Drug: Three repeated
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three repeated doses of GO-ON (2.5 mL each)
Trial: 32129141
Drug: Cost of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost of single-dose injection
Trial: 33201535
Drug: 0.1, 0.2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1, 0.2, or 0.3 mg/kg bumetanide
Trial: 35272940
Drug: Vasopressin injection
RxNorm normalized name: Vasopressin Injection
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasopressin injection during ovarian cystectomy
Trial: 35272940
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no vasopressin injection)
Trial: 36227421
Drug: Ropivacaine group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine group (group N, 0.375% ropivacaine 40 ml + normal saline 4 ml)
Trial: 36227421
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate group (group M, 0.375% ropivacaine 40 ml + 10% magnesium sulfate 4 ml)
Trial: 36227421
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (group C, normal saline 44 ml)
Trial: 33472301
Drug: Betahistine (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine (12 mg orally three times a day for four weeks)
Trial: 32499125
Drug: PEG 4000
RxNorm normalized name: PEG 4000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG 4000 (20 g/d for IBS-C) / Pinaverium bromide (150 mg/d for IBS-D)
Trial: 34116873
Drug: 3-antigen hepatitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-antigen hepatitis B vaccine (3A-HBV) lot A
Trial: 34116873
Drug: 3-antigen hepatitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-antigen hepatitis B vaccine (3A-HBV) lot B
Trial: 34116873
Drug: 1-antigen hepatitis
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-antigen hepatitis B vaccine (1A-HBV) Engerix-B
Trial: 32193758
Drug: Model performance
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model performance with external data from drug banks and ZINC database
Trial: 32193758
Drug: Misclassified non-drug
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misclassified non-drug small molecules
Trial: 33482247
Drug: Imatinib, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib, 400 mg daily for 2 years
Trial: 33482247
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further therapy after surgery
Trial: 33727409
Drug: Early antihypertensive
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early antihypertensive treatment, aimed at average systolic BP reduction by 10%-20% within the first 24 hours and achieving BP <140/90 mm Hg within 5 days.
Trial: 33727409
Drug: Delayed antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed antihypertensive treatment, no antihypertensive medications for the first 7 days, then achieving BP <140/90 mm Hg after 7 days.
Trial: 34523673
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg daily for 21 days
Trial: 32851636
Drug: Caffeine (6.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6.5 mg·kg‐1 body mass)
Trial: 32851636
Drug: Carbohydrate (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (6 g of maltodextrin rinsed for 10 s)
Trial: 36173609
Drug: Doxycycline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (50 mg once daily for 12 weeks)
Trial: 36158665
Drug: Intravenous paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous paclitaxel 135 mg/m2 plus mFOLFOX6
Trial: 36158665
Drug: Intraperitoneal paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intraperitoneal paclitaxel 80 mg/m2 plus mFOLFOX6
Trial: 35280907
Drug: Sarilumab (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab (single 400 mg dose in two 200 mg subcutaneous injections)
Trial: 33164259
Drug: Clonidine or
RxNorm normalized name: clonidine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine or spironolactone (fourth drug)
Trial: 33164259
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with antihypertensive drugs (first phase V0-V3)
Trial: 36400418
Drug: ANT14 (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANT14 (14 days of antofloxacin-based bismuth quadruple therapy)
Trial: 36400418
Drug: ANT10 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANT10 (10 days of antofloxacin-based bismuth quadruple therapy)
Trial: 36400418
Drug: CLA14 (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLA14 (14 days of clarithromycin-based bismuth quadruple therapy)
Trial: 33599841
Drug: De-escalation treatment
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De-escalation treatment options (cetuximab-based radiotherapy)
Trial: 33599841
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (IC) protocols
Trial: 33755110
Drug: PN-HPT (4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PN-HPT (4.0 mL)
Trial: 33755110
Drug: Placebo (4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4.0 mL normal saline)
Trial: 35232423
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg oral Dydrogesterone daily
Trial: 35232423
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg intramuscular 17α‐OHPC weekly
Trial: 33818170
Drug: Tafluprost (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafluprost (15 mg/ml)
Trial: 33818170
Drug: Bimatoprost (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimatoprost (0.1 mg/ml)
Trial: 32122898
Drug: Intravenous dalbavancin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dalbavancin at 1,500 mg
Trial: 32122898
Drug: Intraperitoneal dalbavancin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal dalbavancin at 1,500 mg
Trial: 35748757
Drug: Active group
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active group (external concurrent occipital and trigeminal neurostimulation)
Trial: 34151818
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapies (non-PMRT group)
Trial: 32106141
Drug: efavirenz (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efavirenz (600 mg daily with NRTIs)
Trial: 32106141
Drug: atazanavir/ritonavir (300/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atazanavir/ritonavir (300/100 mg daily with NRTIs)
Trial: 33657959
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg nano-curcumin
Trial: 32328824
Drug: Endoscopist experience
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL GEL [Quality Metalcraft Experi-Metal Alcohol Antiseptic 80% Topical Solution Hand Sanitizer Non-sterile Solution]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopist experience with <20 G‐POEM procedures
Trial: 32328824
Drug: Endoscopist experience
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL GEL [Quality Metalcraft Experi-Metal Alcohol Antiseptic 80% Topical Solution Hand Sanitizer Non-sterile Solution]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopist experience with >20 G‐POEM procedures
Trial: 35854236
Drug: Toripalimab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab (240 mg) every 3 weeks during concurrent chemoradiotherapy and once every 6 weeks after consolidation chemotherapy for up to 1 year.
Trial: 35854236
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy with intensity modulated radiotherapy and high‐dose rate brachytherapy, along with weekly DDP (40 mg/m2) during radiotherapy and 6 cycles of consolidated chemotherapy (paclitaxel plus DDP) after radiotherapy.
Trial: 35666852
Drug: Budesonide oral
RxNorm normalized name: budesonide Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide oral suspension (BOS) low dose: 0.35 or 0.5 mg; high dose: 1.4 or 2.0 mg
Trial: 34027030
Drug: Atomoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (20 mg daily for two weeks followed by 40 mg daily for two weeks)
Trial: 35045980
Drug: Gastrografin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrografin (100 mL oral dose)
Trial: 34370975
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of renin-angiotensin system inhibitors
Trial: 34370975
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of renin-angiotensin system inhibitors
Trial: 32402681
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy with bevacizumab (6 cycles of FOLFOX/FOLFIRI before and after surgery)
Trial: 32402681
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy with bevacizumab (12 cycles after surgery)
Trial: 32402681
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy with bevacizumab (in subgroup with CEA ≥ 5 ng/mL)
Trial: 32402681
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy with bevacizumab (in subgroup with over 2 liver metastases)
Trial: 32468087
Drug: Nangibotide (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nangibotide (0.3, 1.0, or 3.0 mg/kg/h)
Trial: 36104719
Drug: MRV-MNP and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRV-MNP and placebo (0.9% sodium chloride) subcutaneous injection
Trial: 36104719
Drug: Placebo MNP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo MNP and MRV by subcutaneous injection (MRV-SC)
Trial: 33705543
Drug: Lifestyle or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle or metformin interventions
Trial: 34118609
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral pyridoxine (100-300 mg/kg/day) in combination with ACTH (150 IU/m2/day)
Trial: 34118609
Drug: Standard ACTH
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard ACTH therapy alone
Trial: 35235659
Drug: Exenatide (EXE),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (EXE), 5 μg s.c.
Trial: 35235659
Drug: Dapagliflozin (DAPA),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (DAPA), 10 mg
Trial: 35835685
Drug: Acupressure (36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupressure (36 min, three times weekly for one month)
Trial: 33027644
Drug: Mineralocorticoid receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineralocorticoid receptor antagonists (MRA)
Trial: 34693933
Drug: Nonnucleoside reverse
RxNorm normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonnucleoside reverse transcriptase inhibitor (nNRTI) based ART
Trial: 33567423
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (800 mg + 5 μg Vitamin D)
Trial: 33567423
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (1,000 mg)
Trial: 32847991
Drug: Occupational exposures
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational exposures (22 agents)
Trial: 33798731
Drug: PATH intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PATH intervention (online portal and twice a month phone calls from a PA coach)
Trial: 33798731
Drug: Attention control
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention control group (self-help PA handout and twice a month general health newsletter)
Trial: 33344752
Drug: Intravenous allopregnanolone
RxNorm normalized name: Allopregnanolone
DrugBank: Brexanolone (DB11859)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous allopregnanolone
Trial: 35289043
Drug: Topical latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical latanoprost 0.005% solution
Trial: 32568601
Drug: Weekend physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekend physical therapy services in the sub-acute setting (Phase 2, n = 130)
Trial: 32568601
Drug: Weekend physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekend physical therapy services in the acute setting (Phase 1, n = 117)
Trial: 33913511
Drug: secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: secukinumab 300 mg via subcutaneous injection at baseline, week 1-4, and then every 4 weeks until week 48
Trial: 33913511
Drug: adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adalimumab 40 mg via subcutaneous injection every 2 weeks from baseline until week 50
Trial: 32730096
Drug: Pivotal Response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pivotal Response Treatment
Trial: 32730096
Drug: Robot-assisted Pivotal
RxNorm normalized name: PIVOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted Pivotal Response Treatment
Trial: 35596774
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA) 600 mg once daily for 6 months
Trial: 34920155
Drug: 150 mM
RxNorm normalized name: Tenscare Electrodes Joint 150 mm Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mM calcium lactate solution followed by 0.05% sodium fluoride solution (Ca→F)
Trial: 34920155
Drug: 150 mM
RxNorm normalized name: Tenscare Electrodes Joint 150 mm Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mM calcium lactate solution premixed with 0.05% sodium fluoride solution (CaF2, active control)
Trial: 33827659
Drug: Comprehensive pre‐pregnancy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive pre‐pregnancy lifestyle intervention to promote weight loss with ongoing treatment until conception
Trial: 32553151
Drug: IONIS-DGAT2Rx (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IONIS-DGAT2Rx (250 mg, once weekly for 13 weeks)
Trial: 33211592
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (4.03 mmol) of inorganic nitrate
Trial: 33211592
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (8.06 mmol) of inorganic nitrate
Trial: 34819434
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (open reduction and internal fixation using tension band wiring)
Trial: 34819434
Drug: Non-operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative treatment (boot cast)
Trial: 37690669
Drug: Molnupiravir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molnupiravir (800 mg twice daily for 5 days)
Trial: 35962311
Drug: Ice water
RxNorm normalized name: CVS Electrolyte Solution with Zinc (Rice Water)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ice water injection (250 ml) toward the duodenal papilla at the end of ERCP
Trial: 35962311
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no ice water injection)
Trial: 33136077
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy program for the upper limb
Trial: 32914852
Drug: Family-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based behavioral obesity treatment (FBT) for 4 months
Trial: 35609671
Drug: Escitalopram (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (up to 20 mg)
Trial: 32686487
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment (testing, in-person feedback, and two calls from a care-coordinator)
Trial: 32686487
Drug: Standard-care treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-care treatment (neuropsychological testing and phone feedback)
Trial: 32686487
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment and Standard-care treatment
Trial: 32686487
Drug: Standard-care treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-care treatment
Trial: 33593341
Drug: Passive physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive physical treatment
Trial: 33593341
Drug: Active physical
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active physical treatment
Trial: 37552083
Drug: Inappropriate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate therapy
Trial: 33706065
Drug: Topical ozonated
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ozonated oil, applied twice a day for 60 days
Trial: 33706065
Drug: Placebo (non-ozonated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (non-ozonated oil), applied twice a day for 60 days
Trial: 33770365
Drug: Daratumumab in
RxNorm normalized name: daratumumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab in combination with bortezomib, melphalan, and prednisone (D-VMP)
Trial: 32035692
Drug: Standard chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemoradiation combined with recombinant human endostatin injection (Endostar)